Table 2 Incremental costs, QALYs gained and ICERs for the total New Zealand adult population including a subset of the population with high risk of gastric cancer (Māori), comparing serology and fecal antigen as the screening test, in 2011 with lifetime follow-up of participants
Model output | Total population 25–69 yo | Māori 25-69 yo | Non-Māori 25–69 yo |
|---|---|---|---|
Serology based screening | |||
Men and women | |||
Number cases of gastric cancer averted | 3658 (1252–4425) | 1007 (342–1828) | 2650 (905–4837) |
Percentage cases of gastric cancer averted | 16.5% (5.6%–29.4%) | 21.6% (7.4%–38.6%) | 15.2% (5.2%–27%) |
Number of gastric cancer deaths averted | 2434 (834–4425) | 714 (242–1293) | 1720 (588–3141) |
Percentage gastric cancer deaths averted | 16.6% (5.7%–29.5%) | 21.6% (7.3%–38.6%) | 15.2% (5.2%–27%) |
Total net incremental cost (NZ$ million) | $293 ($272–$314) | $41 ($35–$46) | $252 ($233–$272) |
Total intervention cost (NZ$ million) | $294 ($282–$307) | $41 ($38–$45) | $253 ($242-$264) |
Total cost offsets (NZ$ million) | -$1.5 (-$26.2–$22.9) | -$0.61 (-$7.35–$6.21) | -$0.89 ($-22.7–$21.7) |
Total QALYs gained | 14,200 (5100–26,300) | 4000 (1400–7400) | 10,200 (3653–18974) |
Incremental net cost per participant (NZ$) | $119 ($111–$128) | $137 ($117–$158) | $117 ($108–$126) |
Incremental QALYs gained per participant | 0.0058 (0.0020–0.0107) | 0.0137 (0.0047–0.0252) | 0.0047 (0.0016–0.0087) |
ICER (NZ$ per QALY gained) | $24,600 ($11,300–$57,400) | $12,000 ($5700–$27,600) | $29,600 ($13,400–$69,800) |
Men | |||
Incremental cost per participant (NZ$) | $123 ($113–$134) | $147 ($123–$173) | $120 ($110–$131) |
Incremental QALYs gained per participant | 0.0071 (0.0024–0.0131) | 0.0158 (0.0055–0.0293) | 0.0059 (0.0020–0.0110) |
ICER (NZ$ per QALY gained) | $20,800 ($9800–$47,900) | $11,000 ($5600–$24,300) | $24,300 ($11,300–$57,100) |
Women | |||
Incremental cost per participant (NZ$) | $116 ($108–$124) | $129 ($110–$148) | $114 ($105–$123) |
Incremental QALYs gained per participant | 0.0046 (0.0016–0.0085) | 0.0118 (0.0040–0.0217) | 0.0036 (0.0012–0.0067) |
ICER (NZ$ per QALY gained) | $30,200 ($13, 400–$71,400) | $13,200 ($5900–$31,300) | $38,000 ($16,800–$89,900) |
Fecal antigen based screening | |||
Men and women | |||
Total incremental cost (NZ$ million) | $369 ($350–$389) | $49 ($44–$55) | $320 ($301–$339) |
Total QALYs gained | 15,300 (5400–27,700) | 4200 (1500–7600) | 11,000 (3830–20,200) |
Incremental cost per participant (NZ$) | $150 ($142–$158) | $164 ($147–$182) | $148 ($139–$156) |
Incremental QALYs gained per participant | 0.0061 (0.0022–0.0111) | 0.0142 (0.0051–0.0259) | 0.0050 (0.0018–0.0092) |
ICER (NZ$ per QALY) | $29,000 ($13,600–$65,900) | $13,700 ($6700–$30,500) | $34,900 ($16,300–$79,100) |